VitaPath Genetics Lands $6M Equity Investment | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostics developer VitaPath Genetics has raised $6 million in a private equity financing that was led by MDV-Mohr Davidow Ventures and included an investment from X/Seed Capital.

The company is developing a genetic test for spina bifida, a birth defect that affects the spine and which can be avoided with high doses of folic acid therapy.

The company plans to use the Series A financing to complete the validation of this first assay and to prepare for its commercial launch.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.